Brief: Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results And Provides A Corporate Update

Astria Therapeutics

09/08/2021 21:13

Aug 9 (Reuters) - Catabasis Pharmaceuticals Inc  CATB.O :
    * CATABASIS PHARMACEUTICALS REPORTS SECOND QUARTER 2021
FINANCIAL
RESULTS AND PROVIDES A CORPORATE UPDATE
    * Q2 LOSS PER SHARE $0.89
    * Q2 EARNINGS PER SHARE ESTIMATE $-0.30 -- REFINITIV IBES
DATA
    * EXPECTS TO FILE AN INVESTIGATIONAL NEW DRUG APPLICATION
FOR
QLS-215 IN MID-2022
    * PLANS TO INITIATE A PHASE 1 CLINICAL TRIAL WITH INITIAL
RESULTS
ANTICIPATED BY YEAR END 2022 FOR QLS-215
    * CATABASIS - EXPECTS RESULTS OF THIS TRIAL, IF POSITIVE,
COULD
PROVIDE CLINICAL PROOF OF CONCEPT FOR ACTIVITY & PLASMA
HALF-LIFE IMPROVEMENTS FOR QLS-215

Source text for Eikon:  ID:nBw81TDlha 
Further company coverage:  CATB.O 

 ((Reuters.Briefs@thomsonreuters.com;))